Edition:
United States

Endologix Inc (ELGX.OQ)

ELGX.OQ on NASDAQ Stock Exchange Global Select Market

4.05USD
23 Feb 2018
Change (% chg)

$0.01 (+0.25%)
Prev Close
$4.05
Open
$4.04
Day's High
$4.09
Day's Low
$4.02
Volume
99,954
Avg. Vol
154,967
52-wk High
$7.66
52-wk Low
$3.75

Chart for

About

Endologix, Inc. is engaged in developing, manufacturing, marketing and selling medical devices for the treatment of aortic disorders. The Company's products are intended for the treatment of abdominal aortic aneurysms (AAA). The AAA products are built on one of two platforms, including traditional minimally invasive endovascular... (more)

Overall

Beta: 0.42
Market Cap(Mil.): $338.40
Shares Outstanding(Mil.): 83.45
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 33.67 16.59
EPS (TTM): -- -- --
ROI: -- 14.21 35.07
ROE: -- 16.88 17.79

BRIEF-Endologix Inc CEO John McDermott Steps Down

* JOHN MCDERMOTT STEPS DOWN AS CHIEF EXECUTIVE OFFICER OF ENDOLOGIX, INC.

Feb 21 2018

BRIEF-Endologix Posts Q4 Loss Per Share $0.17

* ENDOLOGIX REPORTS FOURTH QUARTER AND FISCAL YEAR 2017 FINANCIAL RESULTS

Feb 21 2018

BRIEF-Endologix Completes Patient Enrollment In The Elevate IDE Clinical Study

* ENDOLOGIX, INC. COMPLETES PATIENT ENROLLMENT IN THE ELEVATE IDE CLINICAL STUDY Source text for Eikon: Further company coverage:

Feb 05 2018

BRIEF-Endologix- On Jan 5, Co Delivered Notice Of Termination To Deerfield Elgx Revolver As Agent Under Credit, Security Agreement Dated As Of April 3, 2017

* ENDOLOGIX- ON JAN 5, CO DELIVERED NOTICE OF TERMINATION TO DEERFIELD ELGX REVOLVER AS AGENT UNDER CREDIT, SECURITY AGREEMENT DATED AS OF APRIL 3, 2017

Jan 08 2018

BRIEF-Endologix Q3 loss per share $0.17

* Q3 earnings per share view $-0.17 -- Thomson Reuters I/B/E/S Source text for Eikon: Further company coverage:

Nov 07 2017

BRIEF-Endologix appoints John Onopchenko as chief operating officer

* Endologix appoints John Onopchenko as chief operating officer Source text for Eikon: Further company coverage:

Oct 19 2017

BRIEF-Endologix says operations not materially affected by Santa Rosa fires‍​

* Comments on impact of the Santa Rosa fires impact on co's facility ‍​

Oct 12 2017

BRIEF-ENDOLOGIX GETS FDA NOD TO BEGIN CONFIRMATORY CLINICAL STUDY ON ITS NELLIX EVAS SYSTEM

* ENDOLOGIX RECEIVES IDE APPROVAL FOR THE EVAS2 CONFIRMATORY CLINICAL STUDY TO EVALUATE THE NELLIX® ENDOVASCULAR ANEURYSM SEALING SYSTEM

Oct 06 2017

BRIEF-Endologix announces CE Mark approval for Nellix Endovascular Aneurysm Sealing System

* Endologix announces CE Mark approval for the Nellix Endovascular Aneurysm Sealing System with the refined indications for use

Sep 21 2017

BRIEF-Endologix announces collaboration agreements with Japan Lifeline

* Endologix announces collaboration agreements with Japan Lifeline for the development and commercialization of thoracic endovascular systems in Japan

Sep 11 2017

Competitors

Earnings vs. Estimates